Sign In
Buy PRFX
$1.13
+0.130 (+13.00%)
At Close: Aug 04, 2026
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
04:15pm, Friday, 31'st May 2024
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est
PainReform Provides Business Update for the First Quarter of 2024
04:05pm, Wednesday, 15'th May 2024
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est
PainReform Announces Closing of $4 Million Public Offering
02:19pm, Thursday, 18'th Apr 2024
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformula
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
08:30am, Tuesday, 02'nd Apr 2024
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PainReform Provides Year-End Business Update
08:00am, Friday, 01'st Mar 2024
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy
PainReform to Present at the Microcap Conference in Atlantic City
08:30am, Monday, 22'nd Jan 2024
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
06:00pm, Tuesday, 26'th Dec 2023
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PainReform Provides Business Update for the Third Quarter of 2023
04:05pm, Wednesday, 15'th Nov 2023
Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd.
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
10:00am, Thursday, 07'th Sep 2023
Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Professor Eli Hazum to Share Positi
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
08:30am, Tuesday, 05'th Sep 2023
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e
PainReform Provides Business Update for the Second Quarter of 2023
04:05pm, Thursday, 10'th Aug 2023
Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fourth quarter of 2023 Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fou
